Evidence map›Paper›PMID 39028192›Full record

ArticleAntimicrobial agents and chemotherapy2024

Rifabutin central nervous system concentrations in a rabbit model of tuberculous meningitis.

Sean Wasserman, Rosleine Antilus-Sainte, Noha Abdelgawad, Narineh M Odjourian, Melissa Cristaldo, Maureen Dougher, Firat Kaya, Matthew Zimmerman, Paolo Denti, Martin Gengenbacher

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sean WassermanInstitute for Infection and Immunity, St. George's, University of London, London, United Kingdom.ORCID 0000-0002-3508-6719
Rosleine Antilus-SainteCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Noha AbdelgawadDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-4907-345X
Narineh M OdjourianCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Melissa CristaldoCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Maureen DougherCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Firat KayaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Matthew ZimmermanCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Paolo DentiDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0001-7494-079X
Martin GengenbacherCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0002-0208-5920

Funding

PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosisU01AI170426 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI SERENA Patricia KOENIG, Sean Wasserman · 2022 to 2026
$5.9M
Translational approaches to improve understanding and outcome in Tuberculous meningitisR01AI145436 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI GENGENBACHER, MARTIN ALFONS, LAI, RACHEL PEI JEN · 2020 to 2024
$3.6M
Characterizing the pharmacokinetics of high dose rifampicin and linezolid in a randomized controlled trial for HIV-associated tuberculous meningitisK43TW011421 · FIC · UNIVERSITY OF CAPE TOWN · PI WASSERMAN, SEAN ADAM · 2019 to 2022
$404k
FIC NIH HHS K43 TW011421HHS | National Institutes of Health (NIH) K43TW011421,U01AI170426HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI145436NIAID NIH HHS R01 AI145436NIAID NIH HHS U01 AI170426
6 · The paper itself

Abstract

Tuberculous meningitis (TBM) has a high mortality, possibly due to suboptimal therapy. Drug exposure data of antituberculosis agents in the central nervous system (CNS) are required to develop more effective regimens. Rifabutin is a rifamycin equivalently potent to rifampin in human pulmonary tuberculosis. Here, we show that human-equivalent doses of rifabutin achieved potentially therapeutic exposure in relevant CNS tissues in a rabbit model of TBM, supporting further evaluation in clinical trials.

Indexed as

Disease Models, AnimalRifabutinTuberculosis, MeningealAnimalsAntibiotics, AntitubercularAntitubercular AgentsCentral Nervous SystemMycobacterium tuberculosisRabbitsRifampinAntibiotics, AntitubercularAntitubercular AgentsRifabutinRifampinMycobacterium tuberculosispreclinical modelsrifamycinssite-of-disease pharmacokineticstuberculous meningitis

Identifiers

PMID39028192
PMCPMC11304741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.